SHetA2

SHetA2 is a derivative of heteroarotinoid, that exhibits cytotoxicity in cancer cells with IC50 of 0.37–4.6 μM. SHetA2 regulates cancer cells differentiation, induces apoptosis through the intrinsic mitochondrial pathway, and arrest cell cycle at G2 phase. SHetA2 exhibits good pharmacokinetic characteristics and antitumor efficacy in mice. SHetA2 is orally active[1][2].

Product Specifications

CAS Number

[361483-66-1]

UNSPSC

12352005

Target

Apoptosis; Caspase; Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sheta2.html

Purity

99.70

Smiles

S=C(NC1=CC=C([N+]([O-])=O)C=C1)NC2=CC3=C(SC(C)(CC3(C)C)C)C=C2

Molecular Formula

C20H23N3O2S2

Molecular Weight

401.55

References & Citations

[1]Zhang Y, et al., High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2. Cancer Chemother Pharmacol. 2006 Nov;58 (5) :561-9.|[2]Benbrook DM, et al., Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists. Invest New Drugs. 2005 Oct;23 (5) :417-28.